Andexanet Alfa与四因子凝血酶原复合物紧急逆转Xa抑制剂相关颅内出血的疗效与安全性:系统评价与Meta分析
该系统评价与Meta分析遵循PRISMA指南,检索截至2024年5月16日的电子数据库,纳入16项研究、共2977例患者,比较Andexanet Alfa(AA)与四因子凝血酶原复合物(4F-PCC)逆转Xa抑制剂相关颅内出血的疗效与安全性。主要终点为成功抗凝逆转、总体死亡率(含30天及住院死亡率)和血栓栓塞事件。结果显示AA组止血效能显著改善(RR 1.10,95%CI 1.01-1.20,P=0.02),总体死亡率更低(RR 0.67,95%CI 0.51-0.88,P=0.004),但30天死亡率无差异(RR 0.82,95%CI 0.58-1.16,P=0.26);AA组血栓栓塞事件更多(RR 1.47,95%CI 1.01-2.15,P=0.046),住院时间更长(MD 0.64,95%CI 0.07-1.22,P=0.03)。ICU住院时间(MD 0.25,95%CI -0.36至0.86,P=0.41)和血肿体积扩大(MD -0.89,95%CI -3.11至1.34,P=0.435)均无显著差异。
要点
- AA组止血效能显著优于4F-PCC(RR 1.10,95%CI 1.01-1.20,P=0.02)。
- AA组总体死亡率显著低于4F-PCC(RR 0.67,95%CI 0.51-0.88,P=0.004),但30天死亡率无差异(RR 0.82,95%CI 0.58-1.16,P=0.26)。
- AA组血栓栓塞事件显著多于4F-PCC(RR 1.47,95%CI 1.01-2.15,P=0.046)。
- AA组住院时间较4F-PCC更长(MD 0.64,95%CI 0.07-1.22,P=0.03),ICU住院时间无差异(MD 0.25,95%CI -0.36至0.86,P=0.41)。
- 两组血肿体积扩大无显著差异(MD -0.89,95%CI -3.11至1.34,P=0.435)。
适用人群与场景
- Xa抑制剂相关颅内出血患者,来自16项研究共2977例。
研究设计与关键结果
- 系统评价与Meta分析,纳入16项研究、共2977例患者,比较AA与4F-PCC逆转Xa抑制剂相关颅内出血的疗效与安全性。
- 主要终点:AA组止血效能显著改善(RR 1.10,95%CI 1.01-1.20,P=0.02);AA组总体死亡率更低(RR 0.67,95%CI 0.51-0.88,P=0.004);30天死亡率无差异(RR 0.82,95%CI 0.58-1.16,P=0.26);AA组血栓栓塞事件更多(RR 1.47,95%CI 1.01-2.15,P=0.046)。
- 次要终点:AA组住院时间更长(MD 0.64,95%CI 0.07-1.22,P=0.03);ICU住院时间无差异(MD 0.25,95%CI -0.36至0.86,P=0.41);血肿体积扩大无差异(MD -0.89,95%CI -3.11至1.34,P=0.435)。
证据类型、等级与局限
- 证据类型:系统评价与Meta分析,遵循PRISMA指南,检索截至2024年5月16日。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,AA在提高止血效能和降低总体及住院死亡率方面优于4F-PCC,但AA的使用可能与更多血栓栓塞事件相关。
- 作者认为,需要更多研究来验证AA在改善止血效能方面的更好结果是否足以弥补其更高的成本和可能的血栓栓塞事件风险。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Factor Xa inhibitors (FXaI) are increasingly used for anticoagulation therapy, yet their association with intracranial hemorrhage poses a significant challenge. Although andexanet alfa (AA) and four-factor prothrombin complex concentrate (4F-PCC) have shown promise in reversing FXaI effects, their comparative efficacy and safety remain uncertain. Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, we conducted a literature search on electronic databases to obtain the relevant studies until May 16, 2024. Our primary outcomes were successful anticoagulation reversal, overall mortality (including 30-day and in-hospital mortality), and thromboembolic events. Secondary outcomes were length of hospital and intensive care unit stay and hematoma volume expansion. Data were pooled using a random-effects model. We included 16 eligible studies with a total of 2,977 patients. A statistically significant improvement in hemostatic efficacy rates was in favor of the AA group (risk ratio [RR] 1.10, 95% confidence interval [CI] 1.01-1.20, P = 0.02). Lower overall mortality rates were found in the AA group (RR 0.67, 95% CI 0.51-0.88, P = 0.004). However, no difference was found in 30-day mortality rates (RR 0.82, 95% CI 0.58-1.16, P = 0.26). In terms of thromboembolic events, more events were found in the AA group (RR 1.47, 95% CI 1.01-2.15, P = 0.046). AA was associated with a longer duration of hospital stay compared to 4F-PCC (mean difference [MD] 0.64, 95% CI 0.07-1.22, P = 0.03). Neither a significant difference in length of intensive care unit stay (MD 0.25, 95% CI - 0.36 to 0.86, P = 0.41) nor a significant difference in hematoma volume expansion was reported (MD - 0.89, 95% CI - 3.11 to 1.34, P = 0.435). Our results suggest that AA is superior to 4F-PCC in enhancing the hemostatic efficacy and reducing the overall and in-hospital mortality rates. More thromboembolic events are thought to be associated with the use of AA. However, more studies are required to validate whether the better results of AA in improving hemostatic efficacy are enough to make up for their higher cost and their possible risk of thromboembolic events.
参考来源
- Sarhan K, Mohamed RG, Elmahdi RR, et al. Efficacy and Safety of Andexanet Alfa Versus Four Factor Prothrombin Complex Concentrate for Emergent Reversal of Factor Xa Inhibitor Associated Intracranial Hemorrhage: A Systematic Review and Meta-Analysis. Neurocrit Care. 2024. PMID: 39379749. doi:10.1007/s12028-024-02130-y
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。